Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-02-10
2010-12-07
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S486000
Reexamination Certificate
active
07846962
ABSTRACT:
Compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and/or its derivatives are described.
REFERENCES:
patent: 4053483 (1977-10-01), Hosta Pujol et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5914431 (1999-06-01), Fennhoff
patent: 2007/0299102 (2007-12-01), Felding et al.
patent: 2521966 (1975-11-01), None
patent: 19638888 (1998-03-01), None
patent: 10202874 (2003-08-01), None
patent: 200400576 (2004-04-01), None
patent: 200400693 (2004-05-01), None
patent: 2004701153 (2004-07-01), None
patent: 200401216 (2004-08-01), None
patent: 1455100 (1976-05-01), None
patent: 7301916 (1995-11-01), None
patent: 8183853 (1996-07-01), None
patent: 2002179649 (2002-06-01), None
patent: 2002179650 (2002-06-01), None
patent: 2003176269 (2003-06-01), None
patent: 1823440 (1996-11-01), None
patent: 03078394 (2003-09-01), None
patent: 2005097107 (2005-10-01), None
patent: 2006083869 (2006-08-01), None
patent: 2006083970 (2006-08-01), None
patent: 2008071387 (2008-06-01), None
patent: 2008129075 (2008-10-01), None
Nicolaou et al., Total Synthesis of Diazonamide A, 2002, Angew. Chem. Int. Ed., 41, No. 18, 3495-3499.
Aktas et al., “Depletion of intracellular Ca2+ stores, phosphorylation of eIF2alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole,”Proc. Natl. Acad. Sci. USA, 95:8280-8285 (1998).
Benzaquen et al., “Clotrimazole inhibits cell proliferation in vitro and in vivo,”Nature Medicine, 1:534-540 (1995).
Bodanszky et al., “Formation of the Peptide Bond,”Peptide Synthesis, Chapter 5, pp. 85-128, John Wiley & Sons, New York (1976).
Golub et al., “Molecular Classification of Cancer: Class discovery and Class Prediction by Gene Expression Monitoring,”Science, 286:531-537 (1999).
Hewawasam et al., “The Synthesis and Characterization of BMS-204352 (MaxiPost™) and Related 3-Fluorooxindoles as Openers of Maxi-K Potassium Channels,”Bioorganic&Medicinal Chemistry Letters, 12:1023-1026 (2002).
Klumpp et al., “Preparation of 3,3-Diaryloxindoles by Superacid-Induced Condensations of Isatins and Aromatics with a Combinatorial Approach,”J. Org. Chem., 63:4481-4484 (1998).
Kozak J., “An Analysis of Vertebrate mRNA Sequences: Intimations of Translational Control,”Cell. Biol., 115:887-903 (1991).
Kozak, “Deteminants of translational fidelity and efficiency in vertebrate mRNAs,”Biochimie, 76:815-821 (1994).
Kozak, “Initiation of translation in prokaryotes and eukaryotes,”Gene, 234:187-208 (1999).
Lala et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors,”Cancer and Metastasis Reviews, 17(1):91-106 (1998).
Miyawaki et al.,Cameleons as Cytosolic and Intra-Organellar Calcium Probes, Oxford University Press: Oxford, London; pp. 3-16 (2001).
Moerke et al., “Small-Molecule Inhibition of the Interaction between the Translation Initiation Factors eIF4E and eIF4G,”Cell.,128:257-267 (2007).
Pain, “Initiation of protein synthesis in eukaryotic cells,”Eur. J. Biochem., 236:747-771 (1996).
Palakurthi et al., “Inhibition of Translation Initiation Mediates the Anticancer Effect of the n-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid,”Cancer Research, 60:2919-2925 (2000).
Palakurthi et al., “Anticancer Effects of Thiazolidinediones Are Independent of Peroxisome Proliferator-Activated Receptor γ . . . ,”Cancer Research, 61:6213-6218 (2001).
Stewart and Young,Solid Phase Peptide Synthesis, pp. 31-34 and 71-82, Pierce Chemical Company, Rockford, IL 1984.
English Abstract of JP2002179649; Jun. 26, 2002; Tsujigami, et al.
English Abstract of JP2002179650; Jun. 26, 2002; Tsujigami, et al.
English Abstract of JP2003176269; Jun. 24, 2003; Ashimori, et al.
Watkins, et al., Translation Initiation and its Deregulation During Tumorigenesis, journal, Feb. 8, 2002, 1023-1027, 86(7), British Journal of Cancer, UK.
Wang, et al., Expression of the Eukaryotic Translation Initiation Factors 4E and 2α in Non-Hodgkin's Lymphomas, journal, Jul. 1999, 247-255, vol. 155 No. 1, American Journal of Pathology, US.
Wang, et al. Expression of Eukaryotic Translation Initiation Factors 4E and 2α Correlates With the Progression of Thyroid Carcinoma, abstract and presentation platform; Mar. 1999, 1101-1107, vol. 11 No. 12, Mary Ann Liebert, Inc., San Francisco.
Rosenwald, The Role of Translation in Neoplastic Transformation From a Pathologist's Point of View, journal, 2004, 3230-3247, Nature Publishing Group, Albuquerque, NM.
Rosenwald, et al., Expression of Translation Initiation Factor eIF-2α is Increased in Benign and Malignant Melanocytic and Colonic Epithelial Neoplasms, journal, Sep. 1, 2003, 1080-1088, vol. 98 No. 5, American Cancer Society.
Meric, et al., Translation Initiation in Cancer: A Novel Target for Therapy, journal, Sep. 2002, 971-979, vol. 1, Houston, TX.
Marintchev, et al., Topology and Regulation of the Human EIF4A/4G/4H Helicase Complex in Translation Initiation, , Feb. 6, 2009, 1-14, Elsevier, Inc.
Natarajan, et al., Journal of Medicinal Chemistry, journal, Oct. 7, 2004, 4978-4981, vol. 47 No. 21, American Chemical Society, Cambridge, MA.
Bilanges, et al., Mechanisms of Translation Deregulation in Human Tumors and Therapeutic Intervention Strategies, journal, Apr. 2, 2007, 5973-5990, USF Cancer Research, San Francisco, CA.
International Preliminary Report on Patentability relating to PCT/US2005/004373, filed Feb. 11, 2005.
Supplementary Partial European Search Report Corresponding to EP 05722960.1 filed Aug. 11, 2006.
Chemical Abstract of Bolotov, V.V., et al., “Synthesis and Antiinflammatory Activity of 3,3-diphenyl-2-oxoindolinecarboxylic Acids and Their Amides” XP002540991.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles. XXXI. Synthesis of 3,3-di-aryloxindoles and 1-methyl-3-oxo-4, 4-diphenyltetrahydroisoquinoline Based on Arylamides of Diphenylchloroacetic and Diphenylalkoxyacetic Acids” XP002540992.
Chemical Abstract of Shklyaev, V.S., et al., “Reactivity of Compounds with a Diarylmethylol Group. XVIII. Cyclization Kinetics of Substituted Anilides of di-p-tolylglycolic and Benzilic Acids” XP002540993.
Chemical Abstract of Barker, Marvin W, et al., “Oxindoles From .alpha.-acyloxyamides” XP002540994.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles. LIII. Case of Deamination During the Acidochromic Cyclization if Arylamides of Diarylglycolic Acids.” XP002540995.
Chemical Abstract of Petyunin, P.A., et al., “Chemistry of Heterocycles. L. Aminoalkylation or 3,3-disubstituted Oxindoles” XP002540996.
Chemical Abstract of Bolotov, V.V., et al., “Synthesis and Antiinflammatory Activity of 3,3-disubsituted 2-oxoindoline-1-acetic Acids and their Derivatives” XP002540997.
Chemical Abstract of Ogata, Masaru, et al., “Synthesis and Antimycotic Properties of 3-(1-imidazolyl)indolin-2-ones” XP002540998.
Natarajan, Amarnath, et al., “3,3-Diaryl-1,3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition” J. Med. Chem. 2004, 47, 1882-1885; XP-002347248.
Aktas Huseyin
Chen Han
Fan Yun-Hua
Halperin José A.
Natarajan Amarnath
Bianchi Kristin
President and Fellows of Harvard College
Saeed Kamal A
LandOfFree
3-3-di-substituted-oxindoles as inhibitors of translation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-3-di-substituted-oxindoles as inhibitors of translation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-3-di-substituted-oxindoles as inhibitors of translation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4237255